NCT01311505View on ClinicalTrials.gov

Bioequivalence Study Comparing Rifampicin In A Fixed-Dose Combination (Rifampicin+Isoniazid, Myrin© 2) And The Reference Drug (Rifampicin, Rimactane®)

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

May 31, 2011

Study Completion Date

May 31, 2011

Conditions
Tuberculosis
Interventions
DRUG

Myrin© 2 (Rifampicin + Isoniazid)

Two (2) fixed-dose combination tablets each containing Rifampicin 150 mg and Isoniazid 75 mg

DRUG

Rimactane® (Rifampicin)

One (1) capsule of Rifampicin 300 mg

Trial Locations (1)

4114

Pfizer Investigational Site, Dasmariñas

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01311505 - Bioequivalence Study Comparing Rifampicin In A Fixed-Dose Combination (Rifampicin+Isoniazid, Myrin© 2) And The Reference Drug (Rifampicin, Rimactane®) | Biotech Hunter | Biotech Hunter